Semi-Solid CDMO Market to Grow with a CAGR of 10.85% through 2029
Increasing Demand for Semi-Solid Formulations and Rising Incidence of
Chronic Diseases are expected to drive the Global Semi-Solid CDMO Market growth
in the forecast period, 2025-2029
According to TechSci Research report, “Semi-Solid
CDMO Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2029F”, the Global Semi-Solid CDMO Market stood at USD 30.98
Billion in 2023 and is anticipated to grow with a CAGR of 10.85% in the
forecast period through 2029.
Pharmaceutical companies are increasingly outsourcing
their development and manufacturing processes to Contract Development and
Manufacturing Organizations (CDMOs) to concentrate on core competencies such as
research and development (R&D) and marketing. This outsourcing strategy
allows companies to reduce operational costs, mitigate risks, and enhance
scalability. As more firms recognize the strategic benefits of partnering with
CDMOs, the demand for semi-solid manufacturing services is anticipated to rise.
Continuous advancements in drug formulation technology
have significantly improved the efficacy and stability of semi-solid products.
Techniques such as nanotechnology, enhanced emulsification processes, and
innovative delivery systems facilitate the development of more effective and
patient-friendly formulations. CDMOs that invest in cutting-edge technology and
facilities are well-positioned to meet the evolving requirements of
pharmaceutical companies, thereby gaining a competitive edge in the market. Regulatory
agencies are increasingly establishing clear and supportive pathways for the
approval of semi-solid formulations. Initiatives aimed at streamlining the
regulatory process help expedite the development and market entry of new
products, encouraging pharmaceutical companies to explore semi-solid
formulations and driving demand for CDMO services.
The industry is also experiencing a shift towards
personalized medicine, wherein treatments are tailored to individual patient
needs. Semi-solid formulations are particularly advantageous in this context,
as they allow for adjustments in dosages and active ingredients based on
patient-specific factors. This trend is prompting pharmaceutical companies to
collaborate with CDMOs that can facilitate the development of customized
semi-solid products. As environmental concerns grow, there is an increasing
emphasis on sustainability within the pharmaceutical sector. CDMOs that
prioritize eco-friendly manufacturing practices and sustainable sourcing of
ingredients are likely to attract clients seeking to enhance their corporate
social responsibility (CSR) profiles. This shift towards sustainable practices
not only meets consumer demand but also positions CDMOs as leaders in an
evolving market landscape.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Semi-Solid CDMO Market”
The Global Semi-Solid CDMO Market is segmented into route
of administration, product, service, end user, regional distribution, and
company.
Based on product, the creams and lotions segment
has emerged as the predominant market leader, The formulation of creams and
lotions allows for the incorporation of various active pharmaceutical
ingredients (APIs), including anti-inflammatory agents, antimicrobial agents,
and moisturizers. This versatility enables the development of targeted therapies
for diverse conditions, such as acne, eczema, and psoriasis. The ability to
tailor the texture and viscosity of creams and lotions caters to different
consumer preferences and therapeutic needs. CDMOs that specialize in these
formulations can develop products that enhance user experience and improve
treatment adherence. The formulation capabilities of creams and lotions
facilitate the development of combination products that deliver multiple
therapeutic benefits. This is particularly advantageous in treating complex
conditions, as multi-functional products can address various symptoms
simultaneously.
The increasing prevalence of skin disorders and the
growing popularity of skincare products are driving demand for creams and
lotions in the semi-solid CDMO market. This trend is supported by heightened
consumer awareness regarding skin health and the efficacy of topical
treatments. The rising prevalence of dermatological conditions, such as acne,
dermatitis, and psoriasis, is creating a surge in demand for effective topical
treatments. Pharmaceutical companies are increasingly focusing on the
development of creams and lotions to address these conditions, leading to
greater reliance on CDMOs for manufacturing. The global cosmetics industry is
experiencing significant growth, with an increasing number of consumers seeking
high-quality skincare products. This demand is driving the development of
innovative creams and lotions, creating opportunities for CDMOs specializing in
semi-solid formulations. As consumers become more informed about the benefits
of active ingredients in skincare products, there is a growing preference for
formulations that deliver visible results. CDMOs that can offer scientifically
backed, effective creams and lotions are well-positioned to capture this market.
Based on region, The Asia Pacific region is experiencing rapid market
growth. The Asia Pacific pharmaceutical market is one of the largest in the
world and is expected to continue growing at a significant rate. This expansion
drives demand for CDMO services, particularly for semi-solid products like
creams, gels, and ointments. Countries such as India, China, and Southeast
Asian nations are emerging as key players in the pharmaceutical landscape. The
increasing number of domestic pharmaceutical companies seeking to enhance their
product offerings will lead to a greater reliance on CDMOs for semi-solid
formulations. Many governments in the region are emphasizing self-sufficiency
in pharmaceutical production. This focus on local manufacturing capabilities
will lead to an uptick in demand for CDMO services.
The increasing consumer awareness regarding skincare
and the growing prevalence of dermatological conditions are driving demand for
semi-solid formulations across Asia Pacific. With a rise in skin-related
ailments, there is an increasing focus on effective topical treatments.
Semi-solid formulations are particularly well-suited for addressing conditions
such as eczema, acne, and psoriasis, prompting pharmaceutical companies to invest
in their development. The cosmetics market in Asia Pacific is experiencing
significant growth, driven by a rising middle class and increasing consumer
spending on beauty products. This trend is leading to higher demand for creams
and lotions, which in turn boosts the semi-solid CDMO market. The shift towards
personalized medicine in the region also fuels demand for semi-solid
formulations. CDMOs can provide customized solutions that cater to individual
patient needs, further enhancing the attractiveness of semi-solid products. Asia
Pacific CDMOs are increasingly investing in advanced manufacturing technologies
and facilities, positioning themselves as competitive players in the global
market. Investments in cutting-edge technologies, such as automation, robotics,
and smart manufacturing, enhance production efficiency and quality. CDMOs in
the region that leverage these advancements can offer superior semi-solid
formulations that meet stringent regulatory standards. The ability to scale
production and adapt to changing market demands is crucial in the semi-solid
CDMO market. Asia Pacific CDMOs are improving their manufacturing capabilities
to provide flexible production options that align with the needs of pharmaceutical
companies. Many Asia Pacific countries offer cost advantages in manufacturing,
including lower labor costs and favorable economic conditions. This cost
competitiveness attracts global pharmaceutical companies looking to outsource
their production needs to CDMOs in the region.
Major companies operating in Global Semi-Solid
CDMO Market are:
- The Lubrizol Corporation
- Cambrex Corporation
- Contract Pharmaceuticals Limited
- Bora Pharmaceuticals
- Ascendia Pharmaceuticals
- Pierre Fabre group
- Piramal Pharma Limited
- DPT Laboratories, LTD
- LGM Pharma
- Pace Analytical Services, LLC
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The Global Semi-Solid CDMO market is poised for
substantial growth, driven by increasing demand for semi-solid formulations,
advancements in formulation technologies, and a strategic shift towards
outsourcing among pharmaceutical companies. With regions like Asia Pacific
leading the charge in market expansion, driven by a burgeoning pharmaceutical
sector and supportive regulatory environments, CDMOs that prioritize
innovation, quality, and customization will be well-positioned to capitalize on
emerging opportunities. As the landscape continues to evolve, collaboration
between pharmaceutical companies and CDMOs will be crucial for developing
effective, patient-centered solutions that meet the complex needs of the
healthcare market. Companies that adapt to these trends and invest in their
capabilities will thrive in this dynamic and competitive environment”, said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Semi-Solid CDMO Market - Global Industry Size, Share, Trends, Opportunity & Forecast Segmented By Route of Administration (Topical, Transdermal, Others), By Product (Ointments, Creams and Lotions, Pastes, Gels, Others), By Service (Contract Development, Contract Manufacturing), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others), By Region, & Competition, 2019-2029F”, has evaluated the future growth potential of Global
Semi-Solid CDMO Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Semi-Solid
CDMO Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com